Our Company
Our mission is to develop life-changing solutions for patients with debilitating eye diseases

Eyevensys is a privately held, clinical-stage biotechnology company. Our first-in-class, non-viral vector gene therapy, sustained drug delivery system offers a new approach to treating major ophthalmic conditions, including chronic non-infectious uveitis, degenerative retinal diseases, retinal vascular diseases, and macular edemas. Together, these illnesses account for the vast majority of vision loss around the globe and significantly impact quality of life for patients of all ages.

Revolutionizing the Treatment of Eye Disease

The Eyevensys technology enables therapeutic proteins to be produced inside the eye—by the eye itself—providing long-lasting treatment effects. It works by administering DNA plasmids directly into the ciliary muscle in the eye, using a process called electrotransfection.

Our novel non-viral gene therapy, sustained ocular drug delivery approach is minimally invasive and offers considerable safety and cost advantages over viral vector gene therapies. It is also more convenient than other intraocular drug delivery approaches, which require repeated intravitreal injection or the insertion of implanted devices.

Dollars raised from investors globally
Average years of ophthalmic disease experience among leadership team members

Our History

Eyevensys was founded in 2008 by Francine Behar-Cohen, MD, PhD, Professor of Ophthalmology at Paris Descartes University. Chief Executive Officer Patricia Zilliox, PhD, has extensive experience developing eye disease treatments, including as head of clinical development at Alcon Laboratories, the world’s largest eye care device company since its 2019 spin-off from Novartis. Most recently, Dr Zilliox served as chief drug development officer at the nonprofit Foundation Fighting Blindness, where she was directly exposed to the full extent of unmet needs in ophthalmology, particularly the need to develop effective treatments for young children with degenerative retinal diseases.

Chief Medical Officer Ronald Buggage, MD, and Chief Scientific Officer Thierry Bordet, PhD, together bring a further 30 years’ ophthalmic and rare disease drug discovery and development experience spanning Big Pharma, biotech, academia, and nonprofit institutions.

Eyevensys is headquartered in Paris, France, with US locations in Cambridge, Massachusetts, and Fort Worth, Texas. The company has raised nearly USD 50 million from European and North American investors.